Survodutide Research Standard

Survodutide (CAS 2805997-46-8), also indexed as BI 456906, is a synthetic peptide dual agonist at the GLP-1 receptor and the glucagon receptor, supplied as a 10 mg lyophilized powder in a 3 mL vial. Like mazdutide it is a unimolecular dual agonist rather than a co-formulation, so its two activities travel on one molecule at a fixed designed ratio.^[1]

Mechanism of Action & Research Context

The molecular targets are the GLP-1 receptor (GLP-1R) and the glucagon receptor (GCGR), both class B GPCRs.

• Two receptors, two contributions. The GLP-1 receptor arm supplies the anorectic and insulinotropic activity; the glucagon receptor arm supplies an energy expenditure effect. Work on unimolecular multi-agonists identifies GcgR activation as the differentiating factor between incretin mono- or dual-agonists and agents that add glucagon — it is what the second receptor is for.^[1]

• The potency ratio is a design parameter. These are not simply two agonists bolted together. Relative receptor potency is empirically optimised, and shifting the ratio changes the pharmacology rather than merely the strength — which is why one dual agonist is not a substitute for another in an experiment.^[1]

• Glucagon engagement is not monotonic. The most useful result for anyone designing a dose-response with this class: in a diet-induced obese mouse model, a long-acting GLP-1R/GCGR dual agonist produced its maximal benefit on hepatic endpoints at a middle dose. The highest dose drove further liver fat reduction and a large induction of oxidative phosphorylation genes, but also exaggerated body weight loss and downregulation of a co-expressed gene module covering steroid hormone biology, bile secretion and retinol metabolism. The authors describe the liver-health benefit of glucagon-receptor engagement as a bell-shaped curve. A design that only tests low and high doses can miss the optimum entirely.^[2]

• Dual agonism outperformed the GLP-1 mono-agonist at matched weight loss. In the same model the dual agonist reduced hepatic steatosis more than semaglutide at equal body weight loss, measured by three independent methods — so the additional effect is attributable to the glucagon arm rather than to weight change alone.^[2]

Research Applications

Primary fields of in vitro and preclinical laboratory investigation include:

• Receptor potency and selectivity assays at GLP-1R and GCGR, including potency-ratio characterisation.^[1]

• Signalling and functional assays in cell lines expressing recombinant or endogenous incretin receptors.^[1]

• Preclinical metabolic models, including diet-induced obese rodents with hepatic histology and transcriptome endpoints.^[2]

• Dose-response design across a range wide enough to detect a non-monotonic optimum.^[2]

• Comparative profiling against GLP-1R mono-agonists at matched body weight.^[2]

Analytical Documentation

Purity and identity vary by manufacturing lot. Kimera Chems does not publish a single fixed purity figure for this item; refer to the batch-specific Certificate of Analysis (COA) issued for the lot received, which reflects third-party analytical testing for that lot.

Storage & Handling

Store at controlled room temperature, sealed and protected from light.

Storage guidance is a house recommendation. Analytical documentation is per-lot release testing.